Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 477 matching trials from the live ClinicalTrials.gov search.
Filters: "DLBCL" Condition: Lymphoma Clear all
Terminated Phase 1 Interventional

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04502706
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
GS-0189, Rituximab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

NCT02038933
View directory record Official record
Conditions
Lymphoma. Non-Hodgkin
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 13, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

NCT02702141
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma, Grade 3 Follicular Lymphoma
Interventions
SGN-CD19B
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 13, 2026, 4:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

NCT03684694
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Interventions
Loncastuximab Tesirine, Ibrutinib
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Orange, California • Redlands, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Phase 2 Interventional

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

NCT05615636
View directory record Official record
Conditions
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
Interventions
Mosunetuzumab, Polatuzumab vedotin, Tafasitamab, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT01691898
View directory record Official record
Conditions
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions
Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

NCT05676450
View directory record Official record
Conditions
Lymphoma
Interventions
cell-free DNA
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02653989
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma, Transformed Indolent Lymphoma
Interventions
MDV9300
Biological
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

NCT02327078
View directory record Official record
Conditions
B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
Interventions
Nivolumab, Epacadostat, Chemotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

NCT03023878
View directory record Official record
Conditions
High-risk Diffuse Large B-Cell Lymphoma
Interventions
Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

NCT02399085
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Bakersfield, California • Los Angeles, California • Redondo Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02926833
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma
Interventions
KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Duarte, California • Palo Alto, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 13, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

NCT02454270
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 13, 2026, 4:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • New Hyde Park, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
KRT-232, acalabrutinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812
View directory record Official record
Conditions
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
113
States / cities
Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

NCT04809467
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
tafasitamab, parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Early Phase 1 Interventional

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

NCT04566978
View directory record Official record
Conditions
Large B-cell Lymphoma, DLBCL
Interventions
89Zr-DFO-REGN3767, PET/CT
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 13, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
CC-122, CC-223, Rituximab, CC-292
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
8
States / cities
Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Phase 1 Interventional

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

NCT06447376
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions
Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
Drug
Lead sponsor
Taylor Brooks
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776
View directory record Official record
Conditions
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
Tulmimetostat, Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Not yet recruiting Phase 1 Interventional

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions
Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation
Drug · Other · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 13, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

NCT02445248
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Tisagenlecleucel, Lymphodepleting chemotherapy
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 13, 2026, 4:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Copanlisib Plus Venetoclax in R/R DLBCL

NCT04572763
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Copanlisib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 13, 2026, 4:32 PM EDT